“…11 However, to date, data for neoadjuvant immunotherapy are scarce, mainly due to the rarity of such tumours in children and adolescents. In adult patients, neoadjuvant immunotherapy of patients with localised MSI-h/dMMR CRC led to excellent treatment responses in two major phase 3 trials.…”